RecruitingPhase 3NCT04766177

Role of Bumetanide in Treatment of Autism

Role of Bumetanide in Treatment of Autism Spectrum Disorder in Children

Sponsor

Sherief Abd-Elsalam

Enrollment

80 participants

Start Date

Jan 1, 2021

Study Type

INTERVENTIONAL

Conditions

Autism

Summary

Role of bumetanide in Autism

Eligibility

Min Age: 3 YearsMax Age: 12 Years

Inclusion Criteria2

All patients with ASD diagnosed by CARS rating Scale⩾30.
Age of patients range between (3-12) years.

Exclusion Criteria1

Patients with ASD associated with neurological antecedents (including epilepsies and febrile seizures), hepatic, renal dysfunction or electrocardiogram abnormalities and syndromatic children(Rett).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBumetanide

bumetanide 0.5 mg twice daily

DRUGPlacebo

placebo tablets twice daily

Locations(1)

Sherief Abd-Elsalam

Tanta, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04766177

Related Trials

Spanish-language Executive Function Intervention for Children With Autism and/or ADHD

NCT070843241 location